Chinese biotech company consolidates gene therapy portfolio
Drug Discovery World
JANUARY 5, 2023
CANbridge Pharmaceuticals has exercised its option to secure the exclusive global rights to develop, manufacture and commercialise a novel gene therapy to treat spinal muscular atrophy (SMA) from UMass Chan Medical School. . The benchmark therapy uses a vector similar to that used in the only gene therapy approved for SMA.
Let's personalize your content